Alberto Villanueva
Oncology Researcher at ICO and Chief of Scientific Office at Xenopat.
Principal investigator of the Drug Resistance Group at ICO-IDIBELL. Bachelor of Biology (1990) and PhD in Genetics (1997) from the University of Barcelona. He performed his postdoctoral studies (1997-2001) in a joint project between Memorial Sloan-Kettering Cancer Center (MSKCC) and Cold Sping Harbour Laboratories. He is internationally renowned through his work on orthotopic PDX (Personal Derived Xenograft), that he named orthoxenografts®. He has used these models not only to study drug resistance acquisition mechanisms (including resistance to cisplatin, 5-fluorouracil and oxaliplatin), but also to develop new antioncogenic drugs and oncogenic personalized treatments. Some of his orthoxenograft® models are unique in the world. He is the author of up to 60 peer-reviewed scientific publications.He has been a key collaborator in projects with several pharmaceutical companies (PharmaMar and others), providing them orthoxenografts® for performing advanced preclinical developments of new anticancer molecules.
Visit website: http://xenopat.com/team/
See also: Catalan Institute of Oncology (ICO) - Public centre working exclusively in the field of cancer.
Details last updated 29-Jul-2020
Alberto Villanueva News
Experts highlight the potential of xenografts in personalized oncology
EurekAlert! - 31-Jan-2017
Patient-derived xenografts are tumour samples that are extracted from patients and reimplanted in...
Read more...